GLP-1 Stocks Are Set to Surge: Here’s Our #1 Biotech Pick

Описание: 🔔 Sign up for daily updates on what Wall Street got wrong: https://getaltimetry.com/?v=EXmu3UmYmAo

GLP-1 stocks are entering a massive new growth phase — and most investors still don’t see what’s coming. In today’s episode, we break down why GLP-1 drugs like Ozempic, Wegovy, Zepbound, and Mounjaro could ignite the next major stock market boom, and reveal our #1 GLP-1 stock pick poised to benefit the most.

You’ll learn:
✔ Why GLP-1 demand is accelerating far beyond weight loss
✔ How inflammation-related benefits expand the total addressable market
✔ What Wall Street is missing in the GLP-1 pricing narrative
✔ Why the GLP-1 opportunity could grow for years — not slow down

Plus, we finish with a 3-Minute Drill on Texas Pacific (TPL) — the overlooked land-driven business that could benefit from energy, water rights, and infrastructure trends tied to America’s next economic boom.

If you’re an investor looking for the next major biotech trend, or you want to understand where the GLP-1 megatrend is heading, this episode breaks it all down.

👍 Leave a comment with the next stock you want us to cover!

⏱ Episode Timestamps:
0:00 – Intro & Episode Overview
0:42 – Trump’s GLP-1 Price Cuts Explained
1:51 – Why Lower Prices May Boost GLP-1 Demand
2:46 – The Bigger GLP-1 Opportunity
4:07 – Novo vs. Eli Lilly: Market Mispricing
5:17 – Uniform Accounting: The REAL Profitability
9:01 – 3-Minute Drill: Texas Pacific (TPL)
14:15 – Wrap-Up & Viewer Requests

#GLP1, #GLP1Stocks, #NovoNordisk, #EliLilly, #Ozempic, #Wegovy, #Zepbound, #Mounjaro, #TrumpRX, #DrugPricing, #BiotechStocks, #PharmaStocks, #StockMarket, #Investing, #UniformAccounting, #TexasPacific, #TPL, #RobSpivey, #JoelLitman, #AltimetryAuthority